|
In response to the fda inspection conducted in (b)(4) 2015, a phase 1 two year retrospective review ((b)(4) 2013 to (b)(4) 2015) ) of all endoscope service work orders was performed in order to identify and assess endoscope malfunctions that may potentially fall within the mdr reportability regulations 21 cfr 803.As a result of that initial phase 1 retrospective review, mdrs were submitted retrospectively.A phase 2 retrospective review for the period of (b)(4) 2015 to (b)(4) 2016, has also been conducted.As a result of the phase 2 review, it was determined that the identified malfunction may trigger, in a worst case scenario the "insertion portion suddenly becomes stiff during the procedure and detected during procedure".However, because there is limited information regarding the underlying event which led to the repair, the company is unable to determine whether the worst case scenario actually occurred and caused any risk to a patient.No known patient injury or death resulted from this event; this mdr is being submitted in an abundance of caution.
|